Completed PHASE2/PHASE3 INTERVENTIONAL NCT00123760

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

Sponsor: AHS Cancer Control Alberta

Conditions Brain Neoplasms Colorectal Neoplasms Lung Neoplasms Lymphoma Thyroid Neoplasms

Interventions Positron Emission Tomography (PET) scan

Updated 5 times since 2017 Last updated: Feb 24, 2016 Started: Feb 29, 2004 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Brain Neoplasms and Colorectal Neoplasms, this trial is completed. The trial is conducted by AHS Cancer Control Alberta and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AHS Cancer Control Alberta
Cross Cancer Institute

Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada